- Home
- IMVT
IMVT
Immunovant Inc.
as 07-26-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $47.93 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.82 - $45.58 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Levine Mark S. | IMVT | Chief Legal Officer | Jul 17 '24 | Sell | $30.55 | 147 | $4,490.85 | 337,409 | SEC Form 4 |
| Levine Mark S. | IMVT | Chief Legal Officer | Jul 17 '24 | Sell | $29.64 | 2,358 | $69,891.12 | 337,556 | SEC Form 4 |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Jul 9 '24 | Sell | $28.06 | 4,747 | $133,200.82 | 350,667 | SEC Form 4 |
| Salzmann Peter | IMVT | Chief Executive Officer | Jul 9 '24 | Sell | $28.06 | 4,619 | $129,609.14 | 1,032,097 | SEC Form 4 |
| Barnett Eva Renee | IMVT | Chief Financial Officer | May 22 '24 | Sell | $29.65 | 4,042 | $119,845.30 | 355,414 | SEC Form 4 |
| Macias William L. | IMVT | Chief Medical Officer | May 22 '24 | Sell | $29.65 | 3,247 | $96,273.55 | 374,403 | SEC Form 4 |
| Butchko Julia G. | IMVT | Chief Development Officer | May 22 '24 | Sell | $29.65 | 3,247 | $96,273.55 | 448,380 | SEC Form 4 |
| Levine Mark S. | IMVT | Chief Legal Officer | May 22 '24 | Sell | $29.65 | 3,242 | $96,125.30 | 339,914 | SEC Form 4 |
| Geffner Michael | IMVT | Chief Medical Officer | Apr 24 '24 | Sell | $28.90 | 3,261 | $94,242.90 | 141,616 | SEC Form 4 |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 24 '24 | Sell | $28.90 | 7,239 | $209,207.10 | 147,739 | SEC Form 4 |
| Levine Mark S. | IMVT | Chief Legal Officer | Apr 24 '24 | Sell | $28.90 | 3,963 | $114,530.70 | 343,156 | SEC Form 4 |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 17 '24 | Sell | $28.80 | 9,479 | $272,995.20 | 362,230 | SEC Form 4 |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 17 '24 | Sell | $29.94 | 2,774 | $83,053.56 | 359,456 | SEC Form 4 |
| Butchko Julia G. | IMVT | Chief Development Officer | Apr 17 '24 | Sell | $28.80 | 7,825 | $225,360.00 | 453,917 | SEC Form 4 |
| Butchko Julia G. | IMVT | Chief Development Officer | Apr 17 '24 | Sell | $29.94 | 2,290 | $68,562.60 | 451,627 | SEC Form 4 |
| Levine Mark S. | IMVT | Chief Legal Officer | Apr 17 '24 | Sell | $28.80 | 7,602 | $218,937.60 | 349,344 | SEC Form 4 |
| Levine Mark S. | IMVT | Chief Legal Officer | Apr 17 '24 | Sell | $29.94 | 2,225 | $66,616.50 | 347,119 | SEC Form 4 |
| Macias William L. | IMVT | Chief Medical Officer | Apr 17 '24 | Sell | $28.80 | 6,136 | $176,716.80 | 379,794 | SEC Form 4 |
| Macias William L. | IMVT | Chief Medical Officer | Apr 17 '24 | Sell | $29.94 | 1,796 | $53,772.24 | 377,998 | SEC Form 4 |
| Macias William L. | IMVT | Chief Medical Officer | Apr 17 '24 | Sell | $28.80 | 269 | $7,747.20 | 377,729 | SEC Form 4 |
| Macias William L. | IMVT | Chief Medical Officer | Apr 17 '24 | Sell | $29.94 | 79 | $2,365.26 | 377,650 | SEC Form 4 |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 17 '24 | Sell | $28.80 | 26,365 | $759,312.00 | 1,060,593 | SEC Form 4 |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 17 '24 | Sell | $29.94 | 7,714 | $230,957.16 | 1,052,879 | SEC Form 4 |
| Butchko Julia G. | IMVT | Chief Development Officer | Apr 9 '24 | Sell | $31.18 | 1,053 | $32,832.54 | 461,742 | SEC Form 4 |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 9 '24 | Sell | $31.18 | 4,807 | $149,882.26 | 1,086,958 | SEC Form 4 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
MT Newswires
7 days ago
Immunovant Insider Sold Shares Worth $257,888, According to a Recent SEC Filing
Argus Research
16 days ago
Daily – Vickers Top Buyers & Sellers for 07/11/2024
Zacks
18 days ago
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Zacks
a month ago
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
MT Newswires
2 months ago
Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Roivant Sciences Ltd Earnings Call
Investor's Business Daily
2 months ago
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.